Zimmer Biomet Holdings, Inc.

The forensic screens point in different directions from the headline growth. The Beneish M-Score is -2.587, which is below -1.78 and therefore not in the elevated manipulation-risk zone; this is a screening result, not a finding that the figures are accurate. The Altman Z"-Score is 3.96, in the safe zone on that model, which indicates the company is not flagged for distress on this measure, but it does not address the refinancing timing shown in the current debt line. The Piotroski F-Score is 6 of 8 computable signals, a broad measure of profitability, leverage and efficiency trends that is solid but not a full pass. Operating cash flow to net income of 2.41 for 2025 reflects large non-cash charges such as amortization, so readers may want to check it against capital expenditure and acquisition spending rather than treat it as a quality mark on its own. Net income fell from $903.8 million in 2024 to $705.1 million in 2025 even as revenue rose 7.2%. The risk factors name Johnson & Johnson MedTech, Stryker and Smith & Nephew as major competitors in knees, hips and S.E.T. products, and competition is described as based on technology, innovation, quality, reputation, customer service and pricing, so margin pressure from that rivalry is a plausible area to watch. The risk factors also flag data privacy and security penalties as a standing exposure. Readers may want to look at Note 16 on commitments and contingencies, which the balance sheet references but which is not included in the excerpt provided.

Catalyst.Per the Q1 2026 10-Q statements, net sales rose to $2,086.7 million from $1,909.1 million, a 9.3% increase, and operating profit rose to $373.2 million from $292.3 million. Net earnings attributable to the company were $238.1 million versus $182.0 million. Restructuring charges fell to $6.3 million from $36.0 million, which helped margins, while SG&A climbed to $849.9 million from $758.8 million. For full year 2025, revenue grew 7.2% to $8.23 billion. The MD&A text supplied is truncated before its narrative on drivers, so the reasons behind these changes are not confirmed here.

Hidden risk.The balance sheet shows a near-term debt step-up. The current portion of long-term debt rose to $1,175.9 million at March 31, 2026 from $587.1 million at December 31, 2025, while cash fell to $424.2 million from $591.9 million. Operating cash flow in Q1 2026 was $359.4 million, down from $382.8 million, and cash went to share repurchases of $250.1 million, dividends of $46.9 million and contingent consideration payments of $69.0 million. Goodwill and intangible assets total $14,479.4 million, about 63.7% of total assets of $22,721.6 million, so an impairment would hit a large share of the asset base.